Profile data is unavailable for this security.
About the company
Shionogi & Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The prescription drug business is engaged in the development of eight new drugs including hypercholesterolemia treatment drugs Crestor, antihypertensive drugs Ilbetan Family (Irbetan, Aimix, Iltra) and antidepressant drugs Sinbalta. The Company is engaged in the provision of information to contribute to medical care by maximizing its products. The over-the-counter (OTC) pharmaceutical business handles products tailored to customers' lifestyles. The in-vitro diagnostics business is engaged in the sale of products, as well as the provision of information on infectious diseases, cardiovascular diseases and allergic diseases. The Company mainly provides its products and services in Japan, Europe and North America markets.
- Revenue in JPY (TTM)418.51bn
- Net income in JPY154.57bn
- Incorporated1919
- Employees4.96k
- LocationShionogi & Co Ltd3-1-8, Dosho-machi, Chuo-kuOSAKA-SHI 541-0045JapanJPN
- Phone+81 662022161
- Fax+81 662299596
- Websitehttps://www.shionogi.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tsumura & Co | 164.61bn | 25.20bn | 375.12bn | 4.14k | 14.72 | 1.26 | 9.79 | 2.28 | 331.93 | 331.93 | 2,167.87 | 3,875.47 | 0.3783 | 0.6916 | 2.48 | 39,781,050.00 | 6.23 | 4.81 | 7.63 | 5.89 | 48.76 | 50.98 | 16.48 | 12.65 | 3.04 | -- | 0.1806 | 32.16 | 7.71 | 4.52 | 1.37 | 2.74 | 17.54 | 5.84 |
| Santen Pharmaceutical Co Ltd | 302.56bn | 26.13bn | 606.64bn | 3.74k | 22.69 | 2.01 | 13.66 | 2.01 | 73.46 | 73.46 | 846.14 | 827.65 | 0.7238 | 2.58 | 3.68 | 80,812,770.00 | 6.25 | 3.31 | 7.77 | 4.10 | 57.92 | 59.73 | 8.64 | 5.21 | 1.97 | 5.38 | 0.1639 | 82.21 | 8.22 | 5.23 | 278.09 | -3.58 | 5.10 | 4.88 |
| Rohto Pharmaceutical Co Ltd | 282.05bn | 27.26bn | 641.93bn | 7.26k | 22.80 | 2.45 | 17.64 | 2.28 | 119.22 | 119.22 | 1,233.69 | 1,109.16 | 0.759 | 2.18 | 4.12 | 38,855,630.00 | 7.37 | 8.54 | 10.29 | 11.79 | 57.38 | 58.59 | 9.71 | 10.30 | 1.29 | -- | 0.1442 | 19.39 | 13.48 | 8.09 | 17.28 | 25.85 | 5.20 | 18.61 |
| Ono Pharmaceutical Co Ltd | 484.30bn | 95.13bn | 870.22bn | 3.85k | 8.67 | 1.05 | 7.69 | 1.80 | 201.26 | 201.26 | 1,026.05 | 1,665.85 | 0.4987 | 2.37 | 3.47 | 125,694,000.00 | 9.80 | 11.95 | 11.16 | 13.73 | 75.38 | 74.11 | 19.65 | 23.89 | 2.80 | -- | 0.1702 | 32.25 | 12.41 | 11.73 | 13.53 | 19.95 | -6.79 | 12.20 |
| Kyowa Kirin Co Ltd | 498.98bn | 83.53bn | 1.33tn | 5.97k | 16.14 | 1.59 | 12.31 | 2.66 | 156.64 | 156.64 | 936.10 | 1,591.79 | 0.4878 | 1.78 | 3.92 | 83,524,780.00 | 8.17 | 6.28 | 9.50 | 7.08 | 74.30 | 75.45 | 16.74 | 14.96 | 3.06 | -- | 0.0276 | 47.25 | 11.01 | 10.25 | 51.55 | 10.52 | 10.28 | 9.86 |
| Eisai Co Ltd | 753.22bn | 40.97bn | 1.38tn | 11.07k | 32.40 | 1.60 | 16.68 | 1.83 | 143.36 | 143.36 | 2,634.81 | 2,905.11 | 0.5673 | 0.8933 | 3.89 | 68,060,180.00 | 3.21 | 5.29 | 4.32 | 7.16 | 79.12 | 76.91 | 5.67 | 8.68 | 1.50 | -- | 0.1781 | 74.13 | -0.3561 | 2.90 | -23.50 | -7.72 | -2.11 | 1.30 |
| Shionogi & Co Ltd | 418.51bn | 154.57bn | 1.83tn | 4.96k | 11.40 | 1.36 | 10.59 | 4.38 | 180.74 | 180.74 | 489.15 | 1,519.70 | 0.292 | 0.9189 | 2.94 | 84,393,830.00 | 10.69 | 12.57 | 11.94 | 14.24 | 85.70 | 84.43 | 36.62 | 37.91 | 6.48 | -- | 0.0088 | 26.77 | 1.97 | 3.41 | -12.40 | 3.38 | 2.17 | 11.22 |
| Astellas Pharma Inc | 1.77tn | 54.75bn | 2.85tn | 14.75k | 51.70 | 1.84 | 11.35 | 1.61 | 30.42 | 30.42 | 986.34 | 854.61 | 0.5060 | 1.36 | 3.39 | 120,113,500.00 | 1.56 | 4.59 | 2.31 | 6.61 | 81.78 | 80.53 | 3.09 | 7.98 | 0.8623 | 15.32 | 0.3774 | 86.61 | 5.60 | 4.19 | -82.73 | -40.17 | 9.62 | 13.00 |
| Otsuka Holdings Co Ltd | 2.27tn | 151.58bn | 5.02tn | 34.39k | 32.20 | 1.94 | 19.08 | 2.21 | 279.51 | 279.51 | 4,183.34 | 4,641.15 | 0.647 | 2.40 | 4.68 | 65,998,690.00 | 4.42 | 4.80 | 5.59 | 5.88 | 71.42 | 68.21 | 6.84 | 8.36 | 1.53 | -- | 0.1173 | 42.16 | 16.14 | 9.33 | -9.18 | 8.07 | 9.27 | 1.92 |
| Takeda Pharmaceutical Co Ltd | 4.55tn | 289.99bn | 6.65tn | 49.28k | 22.99 | 0.9579 | 6.34 | 1.46 | 181.90 | 181.90 | 2,862.68 | 4,365.91 | 0.3088 | 1.31 | 6.25 | 92,248,190.00 | 1.97 | 1.65 | 2.35 | 1.97 | 66.05 | 68.05 | 6.38 | 6.06 | 0.7739 | 3.08 | 0.4219 | 128.42 | 5.87 | 15.25 | -54.56 | 1.28 | 29.09 | 0.8735 |
| Daiichi Sankyo Co Ltd | 1.76tn | 250.40bn | 8.77tn | 18.73k | 34.40 | 5.26 | 27.82 | 4.99 | 130.86 | 130.86 | 918.60 | 855.86 | 0.5913 | 1.01 | 3.73 | 93,883,960.00 | 8.43 | 4.99 | 10.51 | 6.14 | 76.11 | 69.10 | 14.26 | 9.94 | 2.24 | -- | 0.0589 | 51.87 | 25.28 | 11.49 | 85.90 | 16.67 | 13.01 | 16.47 |
Data as of Nov 22 2024. Currency figures normalised to Shionogi & Co Ltd's reporting currency: Japanese Yen JPY
26.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 15 Jun 2023 | 55.21m | 6.21% |
| Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 15 Jun 2023 | 27.11m | 3.05% |
| Nikko Asset Management Co., Ltd.as of 15 Jun 2023 | 26.82m | 3.01% |
| BlackRock Fund Advisorsas of 29 Mar 2024 | 26.80m | 3.01% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 25.34m | 2.85% |
| Daiwa Asset Management Co. Ltd.as of 31 Oct 2024 | 23.31m | 2.62% |
| BlackRock Japan Co. Ltd.as of 29 Mar 2024 | 18.46m | 2.08% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 07 Nov 2024 | 12.85m | 1.45% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 10.34m | 1.16% |
| Geode Capital Management LLCas of 14 Nov 2024 | 9.81m | 1.10% |
More ▼
Data from 30 Jun 2024 - 14 Nov 2024Source: FactSet Research Systems Inc.
